It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety ...

When a study requires an independent Data and Safety Monitoring Board, the patient safety officer can assist the PI with constituting and coordinating the DSMB.

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the Data and Safety Monitoring Board (DSMB) has cleared the continuation of its Phase 1/2 OCU410 ArMaDa clinical trial. This trial is ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and ...

Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI's approval allows Cohort 5 to progress to full enrollment.

A California-based biotech company is turning heads during Tuesday’s session after the company announced its phase 2b COVID-19 trial received Independent Data Safety Monitoring Board (DSMB ...

The company's press release indicated that the enrollment and dosing for the BEACON-IPF trial were voluntarily paused to review data and understand the DSMB's recommendation. While the study remains ...